Statin Therapy Guidelines: What Changed in the 2026 Update

The 2026 update to national statin therapy guidance brings several changes practicing cardiologists and primary care physicians should understand before their next patient visit. This article walks through what changed, what stayed the same, and where the evidence shifted enough to change first-line recommendations.

The most notable revision concerns risk-threshold recalculation for patients aged 40–55 with borderline LDL levels — a population where prior guidance left significant room for clinical judgment.

For patients already established on statin therapy, the update clarifies when a re-evaluation visit is warranted versus when existing therapy can continue unchanged through the next annual review.